Does critical illness cover pay out for skin cancer?
Skin cancer does not have one insurance threshold. An invasive melanoma can meet a full payment definition while still confined to the skin. Other skin cancers are often excluded from that payment, even after surgery, so the tissue report and the exact policy wording matter more than the label.
At a glance
- Some invasive melanomas can meet a full payment definition without spreading elsewhere.
- Melanoma in situ is excluded from the ABI minimum full payment definition.
- Basal cell and squamous cell cancers are usually excluded from the main cancer benefit.
- Some policies offer a smaller benefit with its own skin cancer definition.
Does critical illness cover skin cancer?
Some skin cancers can qualify, but the diagnosis must meet the definition in the policy. A definition is the written medical test for payment. The words skin cancer alone do not establish the type of benefit or the amount payable.
The distinction that can change a claim is invasion into deeper skin versus spread elsewhere in the body. Invasive means cancer has grown beyond the layer where it began. It does not necessarily mean cancer has reached lymph nodes or distant organs.
Melanoma and other skin cancers often have different exclusions. An exclusion is wording that leaves something out of cover. Applying a rule for one type to every skin cancer can wrongly suggest a possible claim has to wait until the cancer spreads.
This guide concerns claims under existing cover. The separate guide to critical illness cover after cancer addresses applications following a diagnosis, which involve a different assessment.
What does the current ABI melanoma definition actually require?
The Association of British Insurers, or ABI, publishes minimum standards for critical illness cover. As checked in November 2026, its live page links to the September 2022 guide with April 2023 clarifications. This sets a minimum standard rather than making every policy identical.
Its cancer definition requires a confirmed malignant tumour with tissue evidence of uncontrolled cancer cell growth and invasion. Malignant means cancerous. For melanoma, it excludes cancers confined to the epidermis, which is the outer layer of skin.
The melanoma exclusion does not say that the cancer must have spread to another organ. Growth beyond the epidermis is a different threshold. A policy following that wording can therefore cover an invasive melanoma that remains localised, subject to its other conditions.
Some contracts use different wording or provide wider benefits. The version issued with an existing policy matters, including any later changes the insurer has confirmed. A current online booklet is not automatically a replacement for the terms of an older policy.
Our guide to critical illness definitions explains the wider role of minimum standards. For skin cancer, the cancer definition and its exclusions need to be read together.
Does stage 1 melanoma count as a critical illness?
It can meet a policy's melanoma definition, even though stage 1 means there is no sign of spread to nearby lymph nodes or other parts of the body. Cancer Research UK explains that staging records thickness and other findings. An early stage label alone cannot settle the insurance question.
Consider Alice, a fictional primary school administrator in Nottingham. Her tissue report records a melanoma measuring 0.6 mm thick, without ulceration, with invasion into the dermis, the layer beneath the epidermis. Her specialist describes it as stage 1A.
Alice sees an online statement suggesting melanoma is covered only after it spreads elsewhere. Her policy instead excludes melanoma confined to the epidermis. The report's confirmation of invasion beneath that layer addresses the melanoma threshold without requiring spread to another organ.
That does not decide every part of her claim. Her insurer still needs to assess the full definition, dates and any individual restrictions. The example shows why the relevant medical finding matters more than a general description of stage 1 as early cancer.
Breslow thickness is the measurement of how deeply a melanoma has grown into the skin. Ulceration means the surface appears broken under a microscope. Those findings help explain a stage, but they are not a substitute for the actual payment definition.
What about melanoma in situ or stage 0?
Melanoma in situ means the cancer cells remain in the epidermis. It is also called stage 0. Cancer Research UK distinguishes this from melanoma that has grown deeper into the skin.
It falls within the ABI minimum definition's exclusions for cancer in situ and melanoma confined to the epidermis. That is why a diagnosis described as melanoma does not always meet the main cancer benefit. The complete diagnosis, including in situ, changes the definition test.
Surgery does not automatically change that result. A procedure can remove a larger area around the original site without establishing that the original cancer invaded beneath the epidermis. The tissue findings and the procedure serve different purposes in assessing cover.
An additional benefit means a separate payment provision alongside the main benefit, often for a smaller amount. Some policies include benefits for specified early cancers, but a general reference to early cancer does not prove melanoma in situ is included. The listed condition and any required treatment still need checking.
For information about the medical meaning of stage 0, Cancer Research UK's page is a useful source. Questions about treatment belong with the clinical team rather than an interpretation of insurance wording.
Is basal cell carcinoma covered by critical illness insurance?
Basal cell carcinoma, often shortened to BCC, and squamous cell carcinoma, or SCC, are the main non-melanoma skin cancers identified by the NHS. They do not inherit the melanoma exception simply because they are cancers of the skin. They are usually excluded from the main cancer benefit.
The current ABI minimum wording has a separate exclusion for other cancers arising from or confined to skin tissue layers. Some policy wordings expressly provide cover where a non-melanoma skin cancer invades lymph glands or spreads to distant organs. That exception needs to appear in the relevant contract rather than be assumed.
Lymph nodes, also called lymph glands, are small structures in the body's lymphatic system. Spread to a distant organ means cancer has reached a different part of the body. Neither is the same finding as growth further into the skin at the original site.
A procedure to remove BCC or SCC does not, on its own, establish entitlement to the full cancer payment. Equally, a main benefit exclusion does not answer whether a separate smaller benefit exists. The two questions need different sections of the policy.
Could there be a smaller skin cancer payment?
Some policies list an additional skin cancer benefit or a benefit for specified early melanomas. These are sometimes described as partial payments, meaning less than the main cover amount. The extra benefit can have a different definition from the main cancer benefit.
An early cancer benefit might cover only named diagnoses or require a specified procedure. A heading that says cancer in situ may also contain exceptions for skin cancers. The benefit name is the starting point for reading, not confirmation that every early skin cancer qualifies.
Imagine Ben, a fictional gardener in Bristol, who has surgery to remove a BCC. His existing policy excludes it from the full cancer payment. He also finds an additional skin cancer heading in his booklet, so the claims team needs to assess that separate definition and any treatment requirement.
Ben's operation does not turn BCC into melanoma or override the main exclusion. It may instead be relevant evidence for the additional benefit. If that benefit pays, the policy conditions state whether the main cover remains intact or is reduced.
The wider guide to cancer and critical illness cover explains cancer benefits beyond skin cancer. Here, the useful distinction is a main benefit decision versus a separate additional benefit decision.
Which evidence matters in a skin cancer claim?
Histology means examining tissue under a microscope. A histology report can identify the tumour type, invasion and other features that a policy definition uses. A diagnosis letter saying skin cancer may be less specific than the evidence the claims team needs.
Useful documents include the policy schedule recording selected cover, the applicable booklet, any individual exclusions and the specialist's reports. A procedural record can also matter where a smaller benefit requires particular treatment. The insurer can identify which medical reports it needs and how it obtains them.
Some policies have a survival period, meaning the insured person must remain alive for a stated period after the insured event. That is separate from the medical threshold for skin cancer. It is also separate from the time needed to gather evidence and decide a claim.
The guide to claiming critical illness cover covers the wider process. For this claim, a useful question is which tissue finding or treatment requirement the insurer says is met, missing or excluded.
What if the wording and the decision seem to conflict?
A written decision can be checked against the precise cancer clause, the skin cancer exclusions and any additional benefit. A protection specialist can help explain how those sections fit together. The medical team can clarify what a report means without being asked to decide an insurance entitlement.
Financial Ombudsman Service decision DRN-3279383 shows why the particular contract matters. It concerned a rare skin-related sarcoma and a wording requiring lymph gland invasion or distant spread for other skin cancers. The complaint was not upheld on the evidence and exclusions in that case.
The ombudsman stressed that each complaint turns on its own facts and policy terms. An online account of someone else's payment therefore cannot establish the result under another contract. This is especially relevant where the same broad cancer name covers different tissue findings.
If an explanation appears to apply a non-melanoma spread requirement to melanoma, the wording can be raised directly with the insurer through its complaint process. Its written response provides a clearer basis for any further review. There is no need to translate a claim decision into a judgement about how serious someone's experience has been.
Questions people ask
Does critical illness cover skin cancer?
Some skin cancers meet a policy definition, especially invasive melanomas growing beyond the epidermis. Other skin cancers are usually excluded from the main cancer benefit, although some policies have additional benefits or specific spread exceptions.
Is basal cell carcinoma covered by critical illness insurance?
It is usually excluded from the full cancer benefit. Some contracts provide a separate skin cancer benefit or an exception for specified spread, so the wording and medical evidence need to be checked together.
Does melanoma have to spread before critical illness cover pays?
Not to another organ under a definition that covers malignant melanoma beyond the epidermis. Invasion beneath that outer skin layer and spread elsewhere are different findings, and the actual policy wording decides the threshold.
Can stage 1 melanoma qualify for a critical illness payout?
It can meet a melanoma definition even while confined to the skin. The tissue findings must be assessed against the contract, including its exclusions and other claim conditions.
Is melanoma in situ covered by critical illness insurance?
It is excluded from the ABI minimum full payment definition because it remains in the epidermis. A separate early cancer benefit may use different wording, but its inclusion cannot be assumed.
Sources
We checked this guide against these sources. It is general information, not advice.
- Guide to minimum standards for critical illness cover, ABIThe current linked guide, dated September 2022 and clarified April 2023, supports the melanoma and other skin cancer exclusions.
- Critical illness cover, ABIConfirms the live link to the guide and that cover varies between policies.
- Stage 1 melanoma skin cancer, Cancer Research UKSupports stage 1 findings, thickness, ulceration and the absence of spread elsewhere.
- Melanoma skin cancer in situ, Cancer Research UKExplains stage 0 and cancer cells remaining in the epidermis.
- What is non-melanoma skin cancer, NHSIdentifies BCC and SCC as the main non-melanoma types.
- What is critical illness cover, MoneyHelperSupports severity requirements and the availability of smaller benefits under some policies.
- Decision DRN-3279383, Financial Ombudsman ServiceDemonstrates a non-melanoma spread clause and assessment using the individual contract and medical evidence.